Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Choline→

Choline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
62-49-7
Molecular formula
C5H14NO+
Molecular weight
104.17 g/mol
Drug class
Essential nutrientprecursor of phosphatidylcholine and acetylcholine
Mechanism of action
Provides a methyl-group donor and precursor for phosphatidylcholine, sphingomyelin and acetylcholine synthesis. Choline is required for membrane integrity, lipid transport, methylation reactions and cholinergic neurotransmission.
Indications / reported uses
  • Prevention and correction of dietary choline deficiency through nutritional intake or supplementation; no general therapeutic drug indication should be inferred from its essential nutrient role

Sources: NIH Office of Dietary Supplements — Choline fact sheet · NLM MeSH — Choline · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Choline Environmental Risk Assessment (ERA) (the Choline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.